<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02082899</url>
  </required_header>
  <id_info>
    <org_study_id>EBI-005-AC-1</org_study_id>
    <nct_id>NCT02082899</nct_id>
  </id_info>
  <brief_title>A Single Center Study for the Treatment of Moderate to Severe Allergic Conjunctivitis (EBI-005-AC-1)</brief_title>
  <official_title>A Single Center, Randomized, Double-Masked, Vehicle-Controlled, Parallel, Group Study to Assess the Efficacy of EBI-005 Topical Ophthalmic Solution for the Treatment of Moderate to Severe Allergic Conjunctivitis Using an Environmental Exposure Chamber (EEC) Model and Conjunctival Allergen Provocation Test (CAPT) Model</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eleven Biotherapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eleven Biotherapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase II Single Center, Randomized, Double-Masked, Vehicle-Controlled, Parallel,&#xD;
      Group Study to Assess the Efficacy of EBI-005 Topical Ophthalmic Solution for the Treatment&#xD;
      of Moderate to Severe Allergic Conjunctivitis Using an Environmental Exposure Chamber (EEC)&#xD;
      Model and Conjunctival Allergen Provocation Test (CAPT) Model. Approximately 150 subjects&#xD;
      will be enrolled and randomized in one study center in Canada for a duration of 0.33 years.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ocular itching in EEC arm at a specific visit comparing EBI-005 vs vehicle</measure>
    <time_frame>17 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Adverse Events.</measure>
    <time_frame>up to 45 days</time_frame>
    <description>Frequency, severity and relationship to study medication of all Adverse Events occurring during the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of antibodies to EBI-005.</measure>
    <time_frame>up to 45 days</time_frame>
    <description>Number and percent of subjects who develop drug antibodies over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of ocular changes</measure>
    <time_frame>up to 45 days</time_frame>
    <description>Changes in ophthalmic examinations over time.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Allergic Conjunctivitis</condition>
  <arm_group>
    <arm_group_label>Active Comparator EBI-005 5 mg/mL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Administered 3 times per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Comparator</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Administered 3 times per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Active Comparator EBI-005 5 mg/mL</intervention_name>
    <arm_group_label>Active Comparator EBI-005 5 mg/mL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Comparator</intervention_name>
    <arm_group_label>Placebo Comparator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Provide written informed consent prior to any study-related procedures.&#xD;
&#xD;
          -  Be 18 years of age or older.&#xD;
&#xD;
          -  Have at least a 2 year history of moderate to severe allergic conjunctivitis.&#xD;
&#xD;
          -  Have a positive skin prick test to ragweed within the past 12 months of Screening&#xD;
             (Visit 1A).&#xD;
&#xD;
          -  Have a score of ≥ 2 for staff-assessed ocular redness in at least one region (nasal or&#xD;
             temporal) in each eye and ≥ 2 for subject-assessed ocular itching within the 3.5-hour&#xD;
             period of allergen exposure in the EEC at Visit 1B.&#xD;
&#xD;
          -  Have required more than one anti-allergy pharmaceutical treatments in the past 2 years&#xD;
             to treat ocular symptoms (including oral, topical, nasal treatments).&#xD;
&#xD;
          -  Be able to self-administer topical ophthalmic drops.&#xD;
&#xD;
          -  Avoid any topical or systemic ocular medications during the entire study period.&#xD;
&#xD;
          -  Are willing and able to follow instructions and can be present for the required study&#xD;
             visits for the duration of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Are female and of childbearing potential and unwilling to remain abstinent through 30&#xD;
             days following the last dose of study drug or not willing to use acceptable birth&#xD;
             control methods.&#xD;
&#xD;
          -  Have previously used an IL-1 blocker (e.g., Anakinra, Rilonacept, or Ilaris).&#xD;
&#xD;
          -  Have a known contraindication or hypersensitivities to Anakinra (Kineret®) or any&#xD;
             therapeutic agent targeted to IL-1 or any component of study drug formulation.&#xD;
&#xD;
          -  Current participation in another clinical study involving an experimental treatment or&#xD;
             participation in such a study within 30 days prior to study entry.&#xD;
&#xD;
          -  Require concomitant use of TNF-blocking agents (e.g., Etanercept, Adalimumab,&#xD;
             Infliximab).&#xD;
&#xD;
          -  Have a history of glaucoma or intraocular pressure (IOP) &gt; 25 mmHg at the Visit 1A&#xD;
             (Medical Screening) or a history of elevated IOP within the past year.&#xD;
&#xD;
          -  Have had ocular surgery including laser procedures within the past 12 months of Visit&#xD;
             1A (Medical Screening).&#xD;
&#xD;
          -  Have had contact lens wear within 4 weeks prior to Visit 1A (Medical Screening) or&#xD;
             unwilling to discontinue wear during the study period&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Goldstein, MD</last_name>
    <role>Study Director</role>
    <affiliation>Eleven Biotherapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigation Site</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L4W 1A2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <study_first_submitted>March 4, 2014</study_first_submitted>
  <study_first_submitted_qc>March 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 10, 2014</study_first_posted>
  <last_update_submitted>July 10, 2014</last_update_submitted>
  <last_update_submitted_qc>July 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 11, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Allergic Conjunctivitis</keyword>
  <keyword>Interleukin 1 Receptor Inhibitor</keyword>
  <keyword>Environmental Exposure Chamber</keyword>
  <keyword>Conjunctival Allergen Provocation Test</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Conjunctivitis</mesh_term>
    <mesh_term>Conjunctivitis, Allergic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

